Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging

Janina Krell-Roesch; Martin Rakusa; Jeremy A. Syrjanen; Argonde C. van Harten; Val J. Lowe; Clifford R. Jack; Walter K. Kremers; David S. Knopman; Gorazd B. Stokin; Ronald C. Petersen; Maria Vassilaki; Yonas E. Geda

doi:10.1002/alz.12557

Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging

Janina Krell-Roesch, Martin Rakusa, Jeremy A. Syrjanen, Argonde C. van Harten, Val J. Lowe, Clifford R. Jack, Walter K. Kremers, David S. Knopman, Gorazd B. Stokin, Ronald C. Petersen, Maria Vassilaki, Yonas E. Geda

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: We examined the association between cerebrospinal fluid (CSF)-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms (NPS) in older non-demented adults. Methods: We included 784 persons (699 cognitively unimpaired, 85 with mild cognitive impairment) aged ≥ 50 years who underwent CSF amyloid beta (Aβ42), hyperphosphorylated tau 181 (p-tau), and total tau (t-tau) as well as NPS assessment using Beck Depression and Anxiety Inventories (BDI-II, BAI), and Neuropsychiatric Inventory Questionnaire (NPI-Q). Results: Lower CSF Aβ42, and higher t-tau/Aβ42 and p-tau/Aβ42 ratios were associated with BDI-II and BAI total scores, clinical depression (BDI-II ≥ 13), and clinical anxiety (BAI ≥ 10), as well as NPI-Q–assessed anxiety, apathy, and nighttime behavior. Discussion: CSF Aβ42, t-tau/Aβ42, and p-tau/Aβ42 ratios were associated with NPS in community-dwelling individuals free of dementia. If confirmed by a longitudinal cohort study, the findings have clinical relevance of taking into account the NPS status of individuals with abnormal CSF biomarkers.

Original language	English (US)
Pages (from-to)	4498-4506
Number of pages	9
Journal	Alzheimer's and Dementia
Volume	19
Issue number	10
DOIs	https://doi.org/10.1002/alz.12557
State	Published - Oct 2023

Keywords

Alzheimer's disease
CSF amyloid beta 42
CSF phosphorylated tau
CSF total tau
cerebrospinal fluid biomarkers
neuropsychiatric symptoms
non-demented

ASJC Scopus subject areas

Epidemiology
Health Policy
Developmental Neuroscience
Clinical Neurology
Geriatrics and Gerontology
Cellular and Molecular Neuroscience
Psychiatry and Mental health

Access to Document

10.1002/alz.12557

Cite this

Krell-Roesch, J., Rakusa, M., Syrjanen, J. A., van Harten, A. C., Lowe, V. J., Jack, C. R., Kremers, W. K., Knopman, D. S., Stokin, G. B., Petersen, R. C., Vassilaki, M., & Geda, Y. E. (2023). Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging. Alzheimer's and Dementia, 19(10), 4498-4506. https://doi.org/10.1002/alz.12557

Krell-Roesch, J, Rakusa, M, Syrjanen, JA, van Harten, AC, Lowe, VJ , Jack, CR , Kremers, WK , Knopman, DS, Stokin, GB, Petersen, RC , Vassilaki, M & Geda, YE 2023, 'Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging', Alzheimer's and Dementia, vol. 19, no. 10, pp. 4498-4506. https://doi.org/10.1002/alz.12557

@article{f25c2ce1aca343368f247b265d9b38ec,

title = "Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging",

abstract = "Introduction: We examined the association between cerebrospinal fluid (CSF)-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms (NPS) in older non-demented adults. Methods: We included 784 persons (699 cognitively unimpaired, 85 with mild cognitive impairment) aged ≥ 50 years who underwent CSF amyloid beta (Aβ42), hyperphosphorylated tau 181 (p-tau), and total tau (t-tau) as well as NPS assessment using Beck Depression and Anxiety Inventories (BDI-II, BAI), and Neuropsychiatric Inventory Questionnaire (NPI-Q). Results: Lower CSF Aβ42, and higher t-tau/Aβ42 and p-tau/Aβ42 ratios were associated with BDI-II and BAI total scores, clinical depression (BDI-II ≥ 13), and clinical anxiety (BAI ≥ 10), as well as NPI-Q–assessed anxiety, apathy, and nighttime behavior. Discussion: CSF Aβ42, t-tau/Aβ42, and p-tau/Aβ42 ratios were associated with NPS in community-dwelling individuals free of dementia. If confirmed by a longitudinal cohort study, the findings have clinical relevance of taking into account the NPS status of individuals with abnormal CSF biomarkers.",

keywords = "Alzheimer's disease, CSF amyloid beta 42, CSF phosphorylated tau, CSF total tau, cerebrospinal fluid biomarkers, neuropsychiatric symptoms, non-demented",

author = "Janina Krell-Roesch and Martin Rakusa and Syrjanen, {Jeremy A.} and {van Harten}, {Argonde C.} and Lowe, {Val J.} and Jack, {Clifford R.} and Kremers, {Walter K.} and Knopman, {David S.} and Stokin, {Gorazd B.} and Petersen, {Ronald C.} and Maria Vassilaki and Geda, {Yonas E.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",

year = "2023",

month = oct,

doi = "10.1002/alz.12557",

language = "English (US)",

volume = "19",

pages = "4498--4506",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms

T2 - Mayo Clinic Study of Aging

AU - Krell-Roesch, Janina

AU - Rakusa, Martin

AU - Syrjanen, Jeremy A.

AU - van Harten, Argonde C.

AU - Lowe, Val J.

AU - Jack, Clifford R.

AU - Kremers, Walter K.

AU - Knopman, David S.

AU - Stokin, Gorazd B.

AU - Petersen, Ronald C.

AU - Vassilaki, Maria

AU - Geda, Yonas E.

PY - 2023/10

Y1 - 2023/10

N2 - Introduction: We examined the association between cerebrospinal fluid (CSF)-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms (NPS) in older non-demented adults. Methods: We included 784 persons (699 cognitively unimpaired, 85 with mild cognitive impairment) aged ≥ 50 years who underwent CSF amyloid beta (Aβ42), hyperphosphorylated tau 181 (p-tau), and total tau (t-tau) as well as NPS assessment using Beck Depression and Anxiety Inventories (BDI-II, BAI), and Neuropsychiatric Inventory Questionnaire (NPI-Q). Results: Lower CSF Aβ42, and higher t-tau/Aβ42 and p-tau/Aβ42 ratios were associated with BDI-II and BAI total scores, clinical depression (BDI-II ≥ 13), and clinical anxiety (BAI ≥ 10), as well as NPI-Q–assessed anxiety, apathy, and nighttime behavior. Discussion: CSF Aβ42, t-tau/Aβ42, and p-tau/Aβ42 ratios were associated with NPS in community-dwelling individuals free of dementia. If confirmed by a longitudinal cohort study, the findings have clinical relevance of taking into account the NPS status of individuals with abnormal CSF biomarkers.

AB - Introduction: We examined the association between cerebrospinal fluid (CSF)-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms (NPS) in older non-demented adults. Methods: We included 784 persons (699 cognitively unimpaired, 85 with mild cognitive impairment) aged ≥ 50 years who underwent CSF amyloid beta (Aβ42), hyperphosphorylated tau 181 (p-tau), and total tau (t-tau) as well as NPS assessment using Beck Depression and Anxiety Inventories (BDI-II, BAI), and Neuropsychiatric Inventory Questionnaire (NPI-Q). Results: Lower CSF Aβ42, and higher t-tau/Aβ42 and p-tau/Aβ42 ratios were associated with BDI-II and BAI total scores, clinical depression (BDI-II ≥ 13), and clinical anxiety (BAI ≥ 10), as well as NPI-Q–assessed anxiety, apathy, and nighttime behavior. Discussion: CSF Aβ42, t-tau/Aβ42, and p-tau/Aβ42 ratios were associated with NPS in community-dwelling individuals free of dementia. If confirmed by a longitudinal cohort study, the findings have clinical relevance of taking into account the NPS status of individuals with abnormal CSF biomarkers.

KW - Alzheimer's disease

KW - CSF amyloid beta 42

KW - CSF phosphorylated tau

KW - CSF total tau

KW - cerebrospinal fluid biomarkers

KW - neuropsychiatric symptoms

KW - non-demented

UR - http://www.scopus.com/inward/record.url?scp=85124563417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124563417&partnerID=8YFLogxK

U2 - 10.1002/alz.12557

DO - 10.1002/alz.12557

M3 - Article

C2 - 35142047

AN - SCOPUS:85124563417

SN - 1552-5260

VL - 19

SP - 4498

EP - 4506

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 10

ER -

Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this